Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Shares of Alumis surged after the company said both of its phase three trials of its envudeucitinib drug for moderate-to-severe plaque psoriasis met all primary and secondary endpoints. The stock more ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Psoriasis severity and quality of life appeared to improve with weight-loss interventions in a systematic review.

Learn what collagen is, why it may or may not have benefits for psoriasis, according to experts, and what the research has found so far.

Teal Health, a virtual women's health company on a mission to eliminate cervical cancer in the U.S., today announced the national availability of its at-home cervical cancer screening, which includes ...